[HTML][HTML] Emerging SARS-CoV-2 variant B. 1.1. 7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2
K Müller, P Girl, A Giebl, H von Buttlar, G Dobler… - Journal of Clinical …, 2021 - Elsevier
Spike-specific antibodies contribute significantly to the neutralising activity against SARS-
CoV-2 and are important for the therapeutic effect of convalescent plasma. B. 1.1. 7 is a
recently emerged variant of SARS-CoV-2 that has several mutations in the gene encoding
for the spike-protein. To assess the potential effect these mutations could have on the
neutralising efficacy of antibodies, we evaluated 96 serum samples from convalescent
plasma donors collected before the first occurrence of B. 1.1. 7 and tested their neutralising …
CoV-2 and are important for the therapeutic effect of convalescent plasma. B. 1.1. 7 is a
recently emerged variant of SARS-CoV-2 that has several mutations in the gene encoding
for the spike-protein. To assess the potential effect these mutations could have on the
neutralising efficacy of antibodies, we evaluated 96 serum samples from convalescent
plasma donors collected before the first occurrence of B. 1.1. 7 and tested their neutralising …
